Derek Ratliff, APRN
Psychiatric/Mental Health · Paducah, KYNPI 1861094211
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,406 of the $14,305 with a category attached, or 72.7%. 21 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 39.4% of the total. 2025 is the largest year on record at $6,928, 7.4 times the $938 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- AbbVie$1K
- Johnson & Johnson$1K
- Lundbeck LLC$863
- Otsuka America Pharmaceutical, Inc.$842
- Alkermes, Inc.$785
- plus $4K from 15 others
What the payments were for
- Consulting fees$2,04014%
- Speaking & faculty fees$7655%
- Travel & lodging$9767%
- Food & beverage$10,40673%
- Education$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 114 | $5,636 |
| AbbVie | 111 | $1,336 |
| Johnson & Johnson(2 entities) | 66 | $1,256 |
| Lundbeck LLC | 54 | $863 |
| Otsuka America Pharmaceutical, Inc. | 44 | $842 |
| Alkermes, Inc. | 41 | $785 |
| Teva Pharmaceuticals USA, Inc. | 58 | $698 |
| Neurocrine Biosciences, Inc. | 27 | $560 |
| Vanda Pharmaceuticals Inc. | 21 | $519 |
| E.r. Squibb & Sons, L.L.C. | 30 | $510 |
| Axsome Therapeutics, Inc. | 15 | $495 |
| Supernus Pharmaceuticals, Inc. | 12 | $230 |
| Corium, LLC | 16 | $210 |
| Sunovion Pharmaceuticals Inc. | 9 | $126 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Braeburn Inc. | 2 | $37 |
| USWM, LLC | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Bausch Health US, LLC | 1 | $19 |
| Indivior Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,305 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $219,805 |
| Austedo XrDeutetrabenazine | 30 | $216,472 |
| CaplytaLumateperone Tosylate | 85 | $140,593 |
| VraylarCariprazine Hcl | 85 | $119,005 |
| Abilify MaintenaAripiprazole | 37 | $108,998 |
| Invega SustennaPaliperidone Palmitate | 43 | $108,853 |
| AuvelityDextromethorphan Hbr/Bupropion | 79 | $84,185 |
| RexultiBrexpiprazole | 45 | $64,357 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $38,935 |
| Lurasidone Hcl | 90 | $32,095 |
| QuviviqDaridorexant Hcl | 19 | $9,601 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,383 |
| Paliperidone ErPaliperidone | 18 | $6,736 |
| Asenapine Maleate | 15 | $6,544 |
| Aripiprazole | 85 | $4,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $560 | $219,80527 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $698 | $216,47230 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $842 | $173,35582 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $5,636 | $140,59385 claims |
| AbbVieVraylar | $1,336 | $119,00585 claims |
| Johnson & JohnsonInvega Sustenna | $1,256 | $108,85343 claims |
| Axsome Therapeutics, Inc.Auvelity | $495 | $84,18579 claims |
| Alkermes, Inc.Lybalvi | $785 | $38,93524 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $51 | $9,60119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $50 | $8,38318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Paducah
- Marilee BakerPaducah$8K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.